In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Novo Nordisk A/S105 enrolled

Overview

This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) primary care database.

Study Type

OBSERVATIONAL

Enrollment

105

Conditions

Obesity Overweight

Interventions

LiraglutideDRUG

No treatment given

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: -New initiators of liraglutide (unbranded, or branded prescription, i.e. Saxenda® or Victoza®), who have no liraglutide prescriptions in the twelve months prior to index date (time of first prescription). Patients must be research standard (registered as "acceptable" in the database) with at least one year of up-to-standard registration prior to their index date Exclusion Criteria: -Not applicable

Locations (1)

Novo Nordisk Investigational Site

Soeborg, Denmark

Outcomes

Primary Outcomes

Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only)

Number

Time frame: Less than 6 months before the date of the first prescription

Number of patients with a BMI above or equal to 27 kg/m^2 and below 30 kg/m^2 and 1 or more comorbidities (Saxenda® only)

With at least 1 relevant comorbidity: (Dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and/or other weight related comorbidities)

Time frame: Less than 6 months before the date of the first prescription

Number of patients with a BMI above or equal to 27 kg/m^2 and less than 30 kg/m^2 and no comorbidities (Saxenda® only)

None of the relevant comorbidities: (Dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea and/or other weight related comorbidities)

Time frame: Less than 6 months before the first prescription

Number of patients with BMI below 27 kg/m^2 (Saxenda® only)

Number

Time frame: Less than 6 months before the first prescription

Number of patients with less than 5% weight loss and continuing treatment (Saxenda® only)

Number

Time frame: Week 0 (first prescription) to week 16; week 24

Mean weight loss in patients not treated according to stopping rule (Saxenda® only)

Time frame: Week 0 (first prescription) to week 16; week 24

Number of patients with a BMI not measured (Saxenda® only)

Number

Time frame: Less than 6 months before the first prescription

Number of patients with at least 5% weight loss and continuing treatment (Saxenda® only)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Number of patients fulfilling at least one of the following: 1) a prescription interval corresponding to a daily dose of 3.0 mg, 2) dose information of 3.0 mg per day, or 3) indication of weight management (Victoza® only)

Number of patients with Victoza® prescriptions

Time frame: Within 4-12 weeks from the date of the first prescription

Number of initiators with other GLP-1 receptor agonists prescribed during continued treatment with Saxenda® (Saxenda® only)

Continued treatment is defined as no gaps of more than 30 days between assumed prescription end and the subsequent prescription date

Time frame: From date of first prescription until 24 months

Number of initiators with other products for weight management prescribed during continued treatment with Saxenda® (Saxenda® only)

Continued treatment is defined as no gaps of more than 30 days between assumed prescription end and the subsequent prescription date

Time frame: From date of first prescription until 24 months

Number of patients who have reached 3.0 mg (Saxenda® only)

Number

Time frame: 12 weeks from time of first prescription

Number of patients with a treatment duration of 0-6 months (Saxenda® only)

Number

Time frame: Month 6

Number of patients with a treatment duration of 7-12 months (Saxenda® only)

Number

Time frame: Month 12

Number of patients with a treatment duration of 13-18 months (Saxenda® only)

Number

Time frame: Month 18

Number of patients with a treatment duration of 19-24 months (Saxenda® only)

Number

Time frame: Month 24

Number of patients with a treatment duration of 25-36 months (Saxenda® only)

Number

Time frame: Month 36

Number of patients with a treatment duration of 37-48 months (Saxenda® only)

Number

Time frame: Month 48

Number of patients with a treatment duration of 49-60 months (Saxenda® only)

Number

Time frame: Month 60

Number of patients with ongoing treatment (current users) (Saxenda® only)

Number

Time frame: Month 60